| Non-adjusted model | Adjusted model | ||
---|---|---|---|---|
 | HR (95% CI) | p value | HR (95% CI) | p value |
Whole population (N=1593) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.19 (1.13-1.25) | <0.001 | 1.12 (1.05-1.19) | <0.001 |
Tertile 1 (<5.5Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.5-7.0Â mg/dL) | 0.88 (0.67-1.16) | 0.365 | 0.84 (0.64-1.11) | 0.225 |
Tertile 3 (>7.0Â mg/dL) | 1.58 (1.24-2.02) | <0.001 | 1.27 (0.96-1.68) | 0.097 |
Men (N=897, 56.3%) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.21 (1.13-1.29) | <0.001 | 1.18 (1.09-1.28) | <0.001 |
Tertile 1 (<5.9Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.9-7.4Â mg/dL) | 0.92 (0.64-1.32) | 0.645 | 0.96 (0.65-1.40) | 0.817 |
Tertile 3 (>7.4Â mg/dL) | 2.02 (1.46-2.81) | <0.001 | 1.76 (1.21-2.57) | 0.003 |
Women (N=696, 43.7%) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.15 (1.06-1.26) | 0.001 | 1.01 (0.91-1.12) | 0.902 |
Tertile 1 (<5.1Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.1-6.5Â mg/dL) | 1.19 (0.80-1.77) | 0.387 | 0.80 (0.52-1.22) | 0.300 |
Tertile 3 (>6.5Â mg/dL) | 1.47 (0.99-2.17) | 0.053 | 0.77 (0.49-1.20) | 0.248 |